Clinical outcomes of NK cell immunotherapy (20172019)
| Indication | Source of NK cells | Therapeutic regimen | Outcome | Reference |
| Allogenic PB-NK | Hepatic carcinoma | 20 ՠ106 NK cells/kg on day 1 to day 3, monthly, 16 infusions | 3/16 PR
8/16 SD 5/16 PD PFS was 7.5 months (range, 212 months) | 64 |
| Allogenic PB-NK | Children with intermediate- or high-risk AML | Cyclophosphamide (day -7), fludarabine(days -6 through -2), and subcutaneous interleukin-2 (days -1, 1, 3, 5, 7, and 9), 3.662.2 ՠ106 NK cells/kg were infused on day 0, 45 infusions | 8/21 relapse occurred between 186 and 629 days after NK cell infusion3/21 died of the disease | 65 |
| Allogenic PB-NK | Liver metastases of gastrointestinal carcinoma | 3.112.1 ՠ106 NK cells/kg were infused on day 0, cetuximab intravenously first on day 7, weekly, 7 infusions | 1/9 PR
2/9 SD 5/9 PD 1/9 Rd | 66 |
| Allogenic PB-NK | Children with recurrent/refractory neuroblastoma | hu14.18K322A, 40 mg/m2/dose, days 25, 7 infusions GM-CSF, and IL2 with chemotherapy: cyclophosphamide/topotecan (courses 1,2), irinotecan/temozolomide (courses 3,4), and ifosfamide/carboplatin/etoposide (courses 5,6) 4.759.5 x 106/kg NK cells were administered with courses 2, 4, and 6 | 4/13 CR
4/13 PR 5/13 SD Median time to progression was 274 days (range, 239568 days)10 /13 patients survived 1 year | 67 |
| Allogenic PB-NK | High-risk neuroblastoma | NK cells at one of five dose levels ranging from 1 to 50 x 106 CD3-CD56+ cells/kg | 10/35 CR or PR
8/35 PD 17/35 no response | 68 |
| Allogenic PB-NK | AML
CML MDS | Melphalan (day -7), fludarabine (days -7, -6, -5, and -4). 200 cGy total body irradiation (day -3), 1 ՠ105 to 1 ՠ108/kg/dose NK cells (days -2, -7, and -28). Bone marrow graft was infused fresh on day 0 | 54% developed grade 12 aGVHD; a low incidence of viral complications was observed.
1/13 died of non-relapse mortality 1/13 relapsed 11/13 alive and in remission at last follow-up (median 14.7 months) | 52 |
| Autologous PB-NK | Gastric or colorectal cancer | IgG1 antibodies treated on weeks -3, 3, 6, 10.
NK cells, 3 doses 0.5 ՠ109 cells/injection on week 0, 3 doses 1.0 ՠ109 cells/injection on week 3, 2.0 ձ09 cells/injection on week 6 | 4/6 SD
2/6 PD | 69 |
| Autologous PB-NK | Locally advanced colon carcinoma | Pre-treatment with 5-fluorouracil or oxaliplatin, then patients were treated with chemotherapy combined with NK cells 2.4-4.0 ՠ109/injection | Median PFS 23.5 months
Prevented recurrence Prolonged survival with acceptable adverse effects Poorly differentiated carcinomas | 50 |
| CB-NK | MM | Lenalidomide on days -8 to -2, melphalan on day-7, 5 ՠ106 to 1 ՠ108 CB-NK cells/kg on day -5 and auto-HCT on day 0 | 8/10 CR
Median follow-up of 21 months, 4/10 progressed or relapsed, 2/10 died | 51 |
AML: acute myeloid leukemia; CML: chronic myeloid leukemia; CR: complete response; MDS: myelodysplastic syndrome; MM: multiple myeloma; PD: disease progression; PFS: progression-free survival; PR: partial response; Rd: dissociated response; SD: disease stabilization.